Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Background and Aims: Risk factors for pancreatic neuroendocrine tumors (PNETs) are not well understood. The aim of this systematic review was to assess if diabetes mellitus, smoking, alcohol use, and family history of cancer are risk factors for PNETs. Methods: MEDLINE and abstracts from the European and North American Neuroendocrine Tumor Societies (ENETS and NANETS) were searched for studies published until October 2013. Eligible studies were selected according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Five studies evaluating 4 individual populations were included (study accrual period 2000-2011) into the meta-analysis, involving 827 cases (range 160-309 per study) and 2,407 controls (range 233-924 per study). All studies had a case-control design and described regional series. The pooled adjusted odds ratio was 2.74 (95% CI: 1.63-4.62; p < 0.01; I2 = 60.4%) for history of diabetes, 1.21 (95% CI: 0.92-1.58; p = 0.18; I2 = 45.8%) for ever smoking, 1.37 (95% CI: 0.99-1.91; p = 0.06; I2 = 0.0%) for heavy smoking, 1.09 (95% CI: 0.64-1.85; p = 0.75; I2 = 85.2%) for ever alcohol use, 2.72 (95% CI: 1.25-5.91; p = 0.01; I2 = 57.8%) for heavy alcohol use, and 2.16 (95% CI: 1.64-2.85; p < 0.01; I2 = 0.0%) for first-degree family history of cancer. Conclusions: Diabetes mellitus and first-degree family history of cancer are associated with an increased risk of sporadic PNET. There was also a trend for diagnosis of sporadic PNET associated with heavy smoking. Alcohol use may be a risk factor for PNET, but there was considerable heterogeneity in the meta-analysis. These results suggest the need for a larger, homogeneous, international study for the clarification of risk factors for the occurrence of PNET.

[1]  E. Negri,et al.  Family history and the risk of cancer: genetic factors influencing multiple cancer sites , 2014, Expert review of anticancer therapy.

[2]  Taiping Zhang,et al.  Risk factors for the occurrence of insulinoma: a case-control study. , 2013, Hepatobiliary & pancreatic diseases international : HBPD INT.

[3]  A. Miller,et al.  Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  W. Bamlet,et al.  Risk factors for sporadic pancreatic neuroendocrine tumors (PNETs): Updated results from a single-center case control study. , 2012 .

[5]  P Boffetta,et al.  Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[7]  Geoffrey S. Tobias,et al.  Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) , 2010, International journal of cancer.

[8]  T. O'Dorisio,et al.  Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): A Single-Center Case Control Study , 2010 .

[9]  K. Nakao,et al.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan , 2010, Journal of Gastroenterology.

[10]  A. Scarpa,et al.  Risk Factors for Sporadic Pancreatic Endocrine Tumors: A Case–Control Study of Prospectively Evaluated Patients , 2009, The American Journal of Gastroenterology.

[11]  I. Drozdov,et al.  Neuroendocrine tumor epidemiology , 2008, Cancer.

[12]  Manal M. Hassan,et al.  Risk factors associated with neuroendocrine tumors: A U.S.‐based case–control study , 2008, International journal of cancer.

[13]  T. Fitzgerald,et al.  Changing Incidence of Pancreatic Neoplasms: A 16-Year Review of Statewide Tumor Registry , 2008, Pancreas.

[14]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Manal M. Hassan,et al.  Family History of Cancer and Associated Risk of Developing Neuroendocrine Tumors: A Case-Control Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[17]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[18]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[19]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[20]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[21]  J. Greenson,et al.  Risk of Other Cancers in Individuals with a Family History of Pancreas Cancer , 2007, Journal of gastrointestinal cancer.